| Autor: |
Rosenzweig IB; Department of Pathology, University of Wisconsin, Madison 53792., Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E, Shrago ES, Sondel PM |
| Jazyk: |
angličtina |
| Zdroj: |
Biotherapy (Dordrecht, Netherlands) [Biotherapy] 1990; Vol. 2 (3), pp. 193-8. |
| DOI: |
10.1007/BF02173519 |
| Abstrakt: |
Six patients with confirmed malignant disease received four consecutive weekly cycles of human recombinant interleukin-2 (IL-2) 4 days/week, continuous iv. infusion, 3 X 10(6) U/m2/day. Plasma cholesterol decreased a mean of 7% within 24 hours after IL-2 infusion and decreased by 33% within 4 days. Plasma cholesterol was significantly lower than baseline concentration by day 21 (-21%), and day 25 (-41%) was significantly lower than day 21. Decreased plasma cholesterol was the result of decreased HDL and LDL cholesterol concentrations. Plasma triglyceride demonstrated a mean increase of 46% after 4 days of therapy and remained greater than baseline concentrations at all time points analyzed. Apolipoprotein AI and AII decreased concomitantly with HDL-cholesterol concentrations, whereas apolipoprotein B after an initial mean decrease of 17% during the first cycle was not significantly different from baseline during the fourth cycle. Apolipoprotein E and Lp(a) were not significantly affected by IL-2 treatment. Plasma C-reactive protein (CRP) increased by 79% within 24 hours of therapy, increased by 254% on day 4, then decreased to baseline concentrations by day 21 after 3 days off of IL-2. Day 25 CRP was elevated compared to both baseline and day 21 concentrations. IL-2 induced plasma lipoprotein changes may be due in part to the induction of interferon gamma. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink